Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
ELUT 
Elutia Inc. (ELUT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/18/2025: ELUT (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $3.5
1 Year Target Price $3.5
| 2 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -64.49% | Avg. Invested days 19 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/18/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 23.17M USD | Price to earnings Ratio - | 1Y Target Price 3.5 |
Price to earnings Ratio - | 1Y Target Price 3.5 | ||
Volume (30-day avg) 2 | Beta 0.63 | 52 Weeks Range 0.50 - 4.84 | Updated Date 12/19/2025 |
52 Weeks Range 0.50 - 4.84 | Updated Date 12/19/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.93 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -121.73% | Operating Margin (TTM) -131.06% |
Management Effectiveness
Return on Assets (TTM) -36.48% | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 47591932 | Price to Sales(TTM) 1.07 |
Enterprise Value 47591932 | Price to Sales(TTM) 1.07 | ||
Enterprise Value to Revenue 2.19 | Enterprise Value to EBITDA -3.32 | Shares Outstanding 40349939 | Shares Floating 22541102 |
Shares Outstanding 40349939 | Shares Floating 22541102 | ||
Percent Insiders 3.69 | Percent Institutions 57.42 |
Upturn AI SWOT
Elutia Inc.
Company Overview
History and Background
Elutia Inc. (formerly known as Cambridge Industries) was founded in 1999. It has evolved through various stages, with a recent focus on developing and commercializing innovative medical devices and technologies. Key milestones include strategic acquisitions and shifts in product focus to address emerging market needs in the healthcare sector.
Core Business Areas
- Segment Name 1: Medical Devices
- Segment Name 2: Biotechnology Solutions
Leadership and Structure
Elutia Inc. is led by a management team with extensive experience in the medical device and biotechnology industries. The company operates with a functional organizational structure, encompassing research and development, manufacturing, sales and marketing, and administrative departments.
Top Products and Market Share
Key Offerings
- Product Name 1: Elutia OneFlowu2122 Catheter System - Description: A novel catheter system designed for improved percutaneous transluminal coronary angioplasty (PTCA) procedures. Market Share: Currently limited as it is in early commercialization. Competitors: Boston Scientific (ACROSS system), Abbott Laboratories (XIENCE family).
- Product Name 2: BioGelu2122 Wound Dressing - Description: A biologically derived wound care product for chronic wound management. Market Share: Niche market with established players. Competitors: Smith & Nephew (ALLEVYN), Mu00f6lnlycke Health Care (Mepilex).
Market Dynamics
Industry Overview
The medical device and biotechnology industries are characterized by rapid innovation, stringent regulatory environments, and significant capital investment. The market is driven by an aging global population, increasing prevalence of chronic diseases, and advancements in medical technology.
Positioning
Elutia Inc. aims to position itself as a leader in niche medical device markets through proprietary technologies and a focus on patient outcomes. Its competitive advantage lies in its innovative product pipeline and potential to disrupt existing treatment paradigms.
Total Addressable Market (TAM)
The TAM for the global medical device market is in the hundreds of billions of dollars, with significant growth projected. Elutia Inc. is positioned to capture a segment of this market with its specialized offerings, aiming for substantial growth within its target therapeutic areas.
Upturn SWOT Analysis
Strengths
- Innovative product pipeline
- Experienced management team
- Focus on unmet medical needs
Weaknesses
- Limited market penetration for new products
- Reliance on external funding
- Brand recognition challenges
Opportunities
- Growing demand for advanced medical technologies
- Strategic partnerships and collaborations
- Expansion into new geographic markets
Threats
- Intense competition from established players
- Regulatory hurdles and approval delays
- Changes in healthcare reimbursement policies
Competitors and Market Share
Key Competitors
- Boston Scientific (BSX)
- Abbott Laboratories (ABT)
- Medtronic (MDT)
- Smith & Nephew (SNN)
- Mu00f6lnlycke Health Care (Not publicly traded in the US)
Competitive Landscape
Elutia Inc. faces competition from well-established medical device companies with significant market share, extensive distribution networks, and substantial R&D budgets. Its advantages lie in its specialized focus and potentially disruptive technologies within specific niches.
Growth Trajectory and Initiatives
Historical Growth: Elutia Inc. has demonstrated growth through product development and market entry. Past growth has been fueled by strategic advancements and initial commercialization efforts.
Future Projections: Future growth is projected to be driven by the successful commercialization of its product pipeline, expansion into new markets, and potential strategic partnerships. Analyst estimates would typically focus on revenue growth and path to profitability.
Recent Initiatives: Recent initiatives likely include the ongoing commercial rollout of key products, further clinical studies, and strategic business development activities to secure partnerships or funding.
Summary
Elutia Inc. is a promising company in the medical device sector with innovative products and a strong leadership team. Its primary strengths lie in its novel technologies and focus on unmet medical needs. However, it faces significant challenges from established competitors and the need for substantial funding to achieve broad market penetration. Continued success will depend on effective commercialization strategies, regulatory navigation, and securing sufficient capital for expansion.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company filings with the U.S. Securities and Exchange Commission (SEC)
- Financial news outlets
- Industry research reports
Disclaimers:
This analysis is based on publicly available information and is for informational purposes only. It does not constitute investment advice. Market share data is approximate and may vary based on reporting methodologies. Financial data for early-stage companies can be volatile and subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Elutia Inc.
Exchange NASDAQ | Headquaters Silver Spring, MD, United States | ||
IPO Launch date 2023-09-07 | Co-Founder, President, CEO & Director Dr. C. Randal Mills Ph.D. | ||
Sector Healthcare | Industry Medical Devices | Full time employees 51 | Website https://elutia.com |
Full time employees 51 | Website https://elutia.com | ||
Elutia Inc., a commercial-stage company, develops and commercializes drug-eluting biologics products for neurostimulation and breast reconstruction in the United States. It operates in three segments: Device Protection, Women's Health, and Cardiovascular. The company offers EluPro, which is used to accommodate cardiac implantable electronic devices, such as pacemakers and internal defibrillators; and CanGaroo, which mitigates complications derived from implantable electronic devices and shortcomings of synthetic envelopes. It also provides ProxiCor for cardiac tissue repair and pericardial closure; Tyke, an extracellular material that is used in the repair of cardiac structures for neonate and infant patients; and VasCure, a patch material used to repair or reconstruct the peripheral vasculature. In addition, the company offers SimpliDerm, which uses human acellular dermal matrices for tissue repair and reconstruction in various applications, such as sports medicine, hernia repair, trauma reconstruction, and breast reconstruction. It serves hospitals and healthcare facilities through its direct sales force, commercial partners, independent sales agents, and distributors. The company was formerly known as Aziyo Biologics, Inc. and changed its name to Elutia Inc. in September 2023. Elutia Inc. was incorporated in 2015 and is headquartered in Silver Spring, Maryland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.